NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT01033032 2022-05-03
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT01355705 2018-09-18
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stanford University
Phase 1/2 Completed
NCT01331824 2018-04-23
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01259375 2017-04-17
ARSARC-PI-0010
University of Utah
Phase 2 Completed
NCT01076504 2016-05-05
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00660504 2014-07-18
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Sumitomo Pharma (Suzhou) Co., Ltd.
Phase 3 Completed